Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of necrotizing entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
June 21, 2023
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Patent for Infant Bacterial Therapeutics Has Been Approved in Europe
Details : IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for prevention of Necrotizing Entercolitis (NEC) and sustained feeding tolerance (SFT) among premature infants.
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
June 15, 2023
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBP-9414 for the prevention of necrotizing enterocolitis contains the active substance lactobacillus reuteri, known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. It is a co-evolved human bacterial strain naturally present in br...
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
March 22, 2023
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBP-9414 (lactobacillus reuteri), is a human bacterial strain naturally present in breast milk. IBP-1016 is being developed for gastroschisis (a severe and rare disease affecting infants), to prevent ROP and to prevent antibiotic resistant hospital acqui...
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobitolimod
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Index Pharmaceuticals Gets New Patent for Cobitolimod Granted in Europe
Details : Kappaproct (Cobitolimod) is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9), and previous research has shown clinical efficacy in patients with moderate-to-severe ulcerative colitis.
Product Name : Kappaproct
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : Cobitolimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk,become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants.
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cobitolimod
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InDex Pharmaceuticals Gets New Patent for Cobitolimod Granted in Canada
Details : The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.
Product Name : Kappaproct
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Cobitolimod
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Next recruitment milestone reached in IBT’s Phase III Study
Details : IBT’s Clinical Phase III study of the drug candidate IBP-9414 for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in premature infants, the Connection Study.
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Recruitment of the Smallest Infants in the Connection Study Paused
Details : IBT is currently developing the drug candidate IBP-9414. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk.
Product Name : IBP-9414
Product Type : Probiotic
Upfront Cash : Inapplicable
August 25, 2021
Lead Product(s) : Lactobacillus Reuteri
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable